Abstract: |
We have previously shown that β‐all trans retinoic acid (RA) inhibits macrocellular growth of a multicellular tumor spheroid model for squamous carcinoma, as measured by spheroid size, but allows for continuing DNA synthesis and cell cycle progression, the two being reconciled by a cell death effect. DNA synthesis in the presence of growth inhibition suggested a rationale for examining combination chemotherapy with RA‐inhibited cells. To this aim, we have extended this observation to a series of 8 squamous carcinoma cell lines. Cells were treated with 1 μM RA for 7 days and cell growth parameters monitored. Although growth inhibition ranged from 0% (A431) to approx. 80% (MDA 886Ln), [3H]‐thymidine incorporation (cpm/μg protein) and percent S‐phase (by flow cytometry) in 7‐day RA‐treated cells was equal or higher than in their control vehicle‐treated cells in 7/8 SCC cell lines. Thus RA‐induced growth inhibition is not just cytostasis. Combination therapy was examined with MDA 886Ln, MDA 686Ln, 1483 and A431 cells pre‐treated for 7 days with 1 μM RA followed by cisplatin or 5‐fluorouracil treatment. An increased effectiveness for the combination was shown using 5‐day tetrazolium dye (MTT) growth assays when cells were growth‐inhibited by RA. Computerized analysis of data using median‐effect and isobologram techniques indicated that the interaction of RA with these chemotherapeutic agents was synergistic. With squamous carcinoma, RA treatment inhibits growth while allowing for continuing DNA synthesis, and these RA‐treated, growth‐inhibited cells exhibit increased sensitivity to chemotherapeutic agents. © 1995 Wiley‐Liss, Inc. Copyright © 1995 Wiley‐Liss, Inc., A Wiley Company |
Keywords: |
controlled study; human cell; squamous cell carcinoma; carcinoma, squamous cell; cisplatin; fluorouracil; drug potentiation; antineoplastic agents; cell proliferation; cell survival; cell cycle; cell cycle s phase; cell division; cell line; combination chemotherapy; dose-response relationship, drug; tumor cells, cultured; drug therapy, combination; head and neck neoplasms; dna, neoplasm; retinoic acid; s phase; growth inhibition; tretinoin; human; priority journal; article; support, non-u.s. gov't; support, u.s. gov't, p.h.s.
|